XELOX + Bevacizumab Dosing for Rectal Adenocarcinoma
For rectal adenocarcinoma, the standard XELOX + bevacizumab regimen is: oxaliplatin 130 mg/m² IV on day 1, capecitabine 850-1000 mg/m² PO twice daily for 14 days, and bevacizumab 7.5 mg/kg IV on day 1, repeated every 3 weeks. 1
Detailed Dosing Schedule
Three-Week Cycle Regimen (CapeOX + Bevacizumab):
- Oxaliplatin: 130 mg/m² IV over 2 hours on day 1
- Capecitabine: 850-1000 mg/m² PO twice daily for 14 days (days 1-14)
- Bevacizumab: 7.5 mg/kg IV on day 1
- Cycle: Repeat every 3 weeks 1
Critical Dosing Considerations
Capecitabine Dose Selection:
Start with 1000 mg/m² twice daily for good performance status patients, with close monitoring in the first cycle. 1 The evidence indicates that while European trials used 1000 mg/m² as standard, North American patients experience greater fluoropyrimidine toxicity and may require dose reduction to 850 mg/m² 1, 2. The relative efficacy of lower starting doses has not been established in large randomized trials, but clinical practice supports individualized dosing based on geographic location and early toxicity assessment.
Bevacizumab Administration:
Bevacizumab can be safely administered at an accelerated rate of 0.5 mg/kg/min (7.5 mg/kg over 15 minutes) rather than the traditional 30-90 minute infusion 1. This is a validated time-saving modification.
Context-Specific Applications
Neoadjuvant Setting (Locally Advanced Rectal Cancer):
For high-risk locally advanced rectal cancer, the regimen has been studied as:
- 3-4 cycles of XELOX + bevacizumab (same doses as above) as induction chemotherapy
- Followed by chemoradiation with capecitabine 825 mg/m² twice daily plus bevacizumab 5 mg/kg every 2 weeks during radiation (45-50.4 Gy)
- Surgery 6-8 weeks after completing chemoradiation 3, 4, 5
Important surgical timing: Stop bevacizumab at least 6-8 weeks before planned surgery to minimize wound healing complications 6, 4, 5.
Metastatic Setting:
For first-line metastatic colorectal cancer (which includes rectal primaries), continue treatment until disease progression. The NO16966 trial established this regimen's efficacy with median PFS of 9.4 months 7. However, only 29% of patients in that trial continued bevacizumab until progression, suggesting suboptimal treatment duration may limit benefit.
Safety Monitoring
Common Grade 3/4 Toxicities:
- Diarrhea: 10-16% (higher during neoadjuvant phase)
- Hand-foot syndrome: 11-57% (all grades)
- Neutropenia: 6-13%
- Thrombocytopenia: 4%
- Asthenia/fatigue: 4-8% 3, 4, 5
Dose Modification Algorithm:
For Grade 2 toxicity during 14-day treatment: Interrupt capecitabine until resolved to grade 0-1, then resume at same dose within the cycle. Do not replace missed doses 8.
For Grade 3 toxicity: Interrupt treatment until resolved to grade 0-1, then resume at 75% of original capecitabine dose (approximately 650-750 mg/m² twice daily). Consider reducing oxaliplatin to 100 mg/m² if neurotoxicity develops 8.
For Grade 4 toxicity: Discontinue treatment permanently 8.
Critical Warnings
Bevacizumab contraindications: Do not use within 28 days of major surgery or in patients with uncontrolled hypertension, recent arterial thrombotic events, or active bleeding. Risk of stroke and arterial events increases in patients ≥65 years 1.
Oxaliplatin neurotoxicity: Strongly consider discontinuing oxaliplatin after 3-4 months (or sooner if ≥grade 2 neurotoxicity), while continuing capecitabine and bevacizumab until progression 1. Oxaliplatin can be reintroduced later if discontinued for neurotoxicity rather than progression.
Renal function: Patients with diminished creatinine clearance require capecitabine dose modification 2, 1. Calculate creatinine clearance before each cycle.